CD38 antigen is a 45 Kd type II glycoprotein normally expressed on plasma cells, B-cell precursors and activated T-lymphocytes.
| Inventor | Institute |
|---|---|
| Francisco Ruíz-Cabello Osuna, Miguel Ángel López-Nevot and Federico Garrido Torres-Puchol | Virgen de las Nieves University Hospital, The Andalusian Health Service |
| Cat. #: | 161690 |
|---|---|
| Tool sub type: | Primary antibody |
| Cancer types: | Blood cancer |
| Research Fields: | Cancer |
| Application: | FACS; IHC; ELISA; WB |
| Target: | CD38 |
| Reactivity: | Human |
| Clone: | GR7A4 |
| Host: | Mouse |
| Class: | Monoclonal |
| Primary citation: | Ruiz-Cabello et al. 1987. Hybridoma. 6(3):275-284. PMID: 3036690 |
| Product description: | CD38 antigen is a 45 Kd type II glycoprotein normally expressed on plasma cells, B-cell precursors and activated T-lymphocytes. |
|---|---|
| Isotype: | IgG1k |
| Molecular weight: | 45 kDA |
| Immunogen: | B-ALL cells |
| Storage buffer: | PBS with 0.02% azide |
|---|---|
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Ruiz-Cabello et al. 1987. Hybridoma. 6(3):275-284. PMID: 3036690 |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151024 | Anti-Hairy [1/24] |
Key Info
Anti-Hairy [1/24]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.